Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

By P. Ascierto, G. McArthur, B. Dréno, V. Atkinson, G. Liszkay, A. D. Di Giacomo, M. Mandalà, L. Demidov, D. Stroyakovskiy, L. Thomas and 11 more. The Lancet Oncology, 2016

877 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/110d81a1a719e3f92fd1879434f5f417f731d76e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. R. Dummer
2. O. Michielin
3. A. V. Akkooi
4. U. Keilholz
5. S. Salomone
6. L. Falzone
7. M. Libra

Citations in the corpus

• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “First-line treatment The current first-line standard of care treatments for unresectable stage III/IV are PD-1 blockade (nivolumab, pembrolizumab), PD-1 blockade (nivolumab) combined with CTLA-4 blockade (ipilimumab) and, in addition for BRAF V600-mutated melanoma [II, B], BRAF inhibition (vemurafen”
• Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium (2018, background): “To overcome these resistance mechanisms, BRAF inhibitors are generally combined with MEK inhibitors, such as Trametinib (Mekinist R ) and/or Cobimetinib (Cotellic R ) (Robert et al., 2015; Ascierto et al., 2016).”